Table 1.
Characteristics of Patients Involved in the Trials From the Lipoprotein(a) Studies Collaboration
| Variables | 4D (n = 1224) | CARDS (n = 2232) | LIPID (n = 7862) | MIRACL (n = 2328) | 4S (n = 4397) | Total (n = 18 043) |
|---|---|---|---|---|---|---|
| Baseline | ||||||
| Age, y | 66 (8) | 62 (8) | 61 (8) | 65 (11) | 59 (7) | 62 (8) |
| Female sex, n (%) | 566 (46) | 715 (32) | 1333 (17) | 784 (34) | 823 (19) | 4221 (23) |
| History of CVD, n (%) | 501 (41) | 6 (0) | 7862 (100) | 2328 (100) | 4397 (100) | 15 094 (84) |
| Diabetes mellitus, n (%) | 1224 (100) | 2232 (100) | 676 (89) | 503 (22) | 200 (5) | 4835 (27) |
| Smoking, n (%) | 107 (9) | 484 (22) | 735 (9) | 674 (29) | 1127 (26) | 3127 (17) |
| SBP, mm Hg | 146 (22) | 144 (16) | 134 (19) | 128 (20) | 139 (20) | 138 (19) |
| Total cholesterol, mg/dL | 219 (43) | 206 (33) | 219 (32) | 206 (37) | 260 (26) | 222 (32) |
| HDL‐C, mg/dL | 36 (13) | 63 (19) | 37 (9) | 47 (12) | 46 (11) | 46 (12) |
| Triglycerides, mg/dL | 223 (149–325) | 142 (97–195) | 140 (104–192) | 162 (122–219) | 128 (97–159) | 142 (106–193) |
| ApoB, mg/dL | 110 (30) | 115 (24) | 133 (25) | … | 116 (18) | 119 (23) |
| Lipoprotein(a), mg/dL | 12 (5–42) | 9 (5–22) | 14 (7–44) | 10 (5–29) | 10 (4–27) | 12 (5–34) |
| “LDL‐C,” mg/dL | 126 (30) | 112 (30) | 150 (29) | 124 (33) | 188 (25) | 140 (29) |
| LDL‐Ccorr30, mg/dL | 116 (33) | 106 (30) | 142 (29) | 118 (33) | 183 (25) | 133 (29) |
| Follow‐up | ||||||
| Duration of follow‐up, y | 2.4 (1.4–3.7) | 4.0 (3.1–4.7) | 5.4 (3.1–6.0) | 0.3 (0.3–0.3) | 5.3 (3.9–5.5) | 4.7 (1.6–5.5) |
| No. of CVD events | 329 | 154 | 3039 | 517 | 1351 | 5390 |
Data shown are means (SDs), medians (interquartile ranges), or counts (percentages). LDL‐Ccorr30 was estimated by subtracting 30% of lipoprotein(a) mass from “LDL‐C”. Descriptive summaries of corrected LDL‐C values assuming other proportions of lipoprotein(a) cholesterol content are provided in Table S3. Total means and SDs were calculated by pooling trial‐specific estimates with random‐effects meta‐analysis. 4D indicates German Diabetes and Dialysis Study; 4S, Scandinavian Simvastatin Survival Study; ApoB, apolipoprotein B; CARDS, Collaborative Atorvastatin Diabetes Study; CVD, cardiovascular disease; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; LIPID, Long‐Term Intervention with Pravastatin in Ischaemic Disease Study; MIRACL, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study; and SBP, systolic blood pressure.